SREBP-1 (Sterol Regulatory Element-Binding Protein 1) activators form a class of chemical compounds designed to influence lipid metabolism by increasing the transcriptional activity of the SREBP-1 protein. This set of molecules is incredibly diverse and includes various categories such as fatty acids, sterols, and even certain pharmacological agents like statins and thiazolidinediones. Some compounds, like palmitic acid, directly interact with cellular pathways to upregulate SREBP-1. Others, such as certain statins, disrupt cholesterol biosynthesis, thereby indirectly triggering a compensatory increase in SREBP-1 levels. Then there are compounds like insulin, which can elevate SREBP-1 activity via PI3K/Akt signaling pathways. The variety of mechanisms through which these activators function is a testament to the central role SREBP-1 plays in cellular metabolism.
Interestingly, the context within which these chemicals operate can significantly influence their effectiveness. Cellular stress conditions, nutrient availability, and even the presence of other signaling molecules can modulate how effectively these compounds activate SREBP-1. For example, high glucose levels have been observed to synergize with certain SREBP-1 activators, enhancing their effect. Additionally, the action of these compounds can be cell-type specific, leading to a range of outcomes depending on the tissue in which SREBP-1 activation occurs. Thus, SREBP-1 activators are not just a chemically diverse group but also exhibit a wide array of actions depending on biological context, making them a fascinating subject of study in the field of cellular metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates the PI3K/Akt pathway, leading to the inhibition of GSK-3β. This series of events stabilizes the SREBP-1 protein, promoting its activity and the expression of lipogenic genes. | ||||||
Palmitic Acid | 57-10-3 | sc-203175 sc-203175A | 25 g 100 g | $114.00 $286.00 | 2 | |
Palmitic acid can trigger ER stress, which in turn activates the SREBP-1 pathway, leading to increased lipid accumulation in cells. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a Thiazolidinedione, rosiglitazone activates PPARγ, which can upregulate the expression of SREBP-1, thus promoting lipid synthesis. | ||||||
D(+)Glucose, Anhydrous | 50-99-7 | sc-211203 sc-211203B sc-211203A | 250 g 5 kg 1 kg | $38.00 $198.00 $65.00 | 5 | |
Elevated glucose levels can trigger the ChREBP pathway, which subsequently activates the SREBP-1 promoter, resulting in increased lipid synthesis. | ||||||
Oleic Acid | 112-80-1 | sc-200797C sc-200797 sc-200797A sc-200797B | 1 g 10 g 100 g 250 g | $37.00 $104.00 $580.00 $1196.00 | 10 | |
This fatty acid can activate SREBP-1 by promoting its translocation from the ER to the Golgi apparatus, where it is processed and activated. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
This polyunsaturated fatty acid can increase SREBP-1 activity through unknown mechanisms, although it's speculated that it might involve modulation of intracellular signaling pathways. | ||||||
T 0901317 | 293754-55-9 | sc-202824 sc-202824A | 10 mg 50 mg | $89.00 $224.00 | 5 | |
As an LXR agonist, T0901317 upregulates SREBP-1c expression indirectly, promoting lipid synthesis. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol esters like PMA can activate Protein Kinase C, which indirectly can lead to increased SREBP-1 levels through the modulation of various signaling pathways. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
This anticancer drug is known to induce lipid accumulation in cells, potentially through activation of SREBP-1, although the exact mechanism is not clearly defined. | ||||||